Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Xavier G. L. V. Pouwels*, Robert Wolff, Bram L. T. Ramaekers, Anoukh Van Giessen, Shona Lang, Steve Ryder, Gill Worthy, Steven Duffy, Nigel Armstrong, Jos Kleijnen, Manuela A. Joore

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)533-543
Number of pages11
JournalPharmacoeconomics
Volume36
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • CHARISMA TRIAL
  • CLOPIDOGREL
  • RATIONALE
  • ASPIRIN
  • DESIGN
  • RISK
  • 1ST

Cite this